SNIPR Biome will use the EIB funds to develop new medicines for infections where existing antibiotics are no longer effective. The EIB’s financing is backed under HERA Invest, part of the European Commission’s InvestEU initiative.
SNIPR receives up to EUR 20 million from European Investment Bank (EIB) to advance therapies against microbial resistance
Previous
Previous
SNIPR announces grant of patent by the European Patent Office protecting the newly-discovered and characterised CRISPR-CasS system
Next
Next